Navigation Links
Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
Date:1/26/2010

THE WOODLANDS, Texas, Jan. 26 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will hold a conference call on Thursday, January 28, 2010 at 11:30 am Eastern Time to discuss its recent top-line Phase 2 clinical results with LX4211, Lexicon's once-per-day, orally-delivered, small molecule drug candidate for the treatment of type 2 diabetes mellitus.  

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 53373071.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has five drug candidates in development for diabetes, autoimmune disease, carcinoid syndrome, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.

RELATED LINKS
http://www.lexpharma.com

'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
(Date:3/29/2017)... , March 29, 2017   Royal Philips ... in health technology, and PathAI, a company that ... with the aim to develop solutions that improve ... cancer and other diseases. The partnership aims to ... this form of artificial intelligence to be applied ...
(Date:3/29/2017)... TEL AVIV, Israel , March 29, 2017 ... license agreement in which Exeltis will obtain exclusive marketing rights for ... ... is an age-appropriate drug targeted to treat sleep disorders in children ... to be the first sleep medication approved for children. ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from Guardian’s ... face in trying to balance both short-term and long-term benefits demands. Are ... the growing complexity, companies are finding that the short-term strategies used to control ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... ... 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is pleased ... Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with ... S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the first technology to directly address the resolution to globally reduce the harmful ... a patented compound of FDA and TTB approved ingredients that when infused into ...
Breaking Medicine News(10 mins):